<DOC>
	<DOC>NCT02957409</DOC>
	<brief_summary>The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.</brief_summary>
	<brief_title>PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Receiving sacubitril/valsartan as per the Canadian product label and treatment initiation within the last 3 months Able to communicate with investigator Participation in a clinical trial of an investigational drug, concurrently, or within the last 30 days Presence of any condition that in the opinion of the investigator, prohibits patient from participating in the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Heart Failure with Reduced Ejection Fraction</keyword>
	<keyword>HFrEF</keyword>
</DOC>